British Journal of Cancer - Table of Contents alert Volume 111 Issue 12

If you are unable to see the message below, click here to view.

TABLE OF CONTENTS Volume 111, Issue 12 (2205-2396) Published online 9 December 2014 In this issue Minireviews Clinical Studies Translational Therapeutics Molecular Diagnostics Genetics and Genomics Letters to the Editor Corrigenda Erratum Index Also new today Advance online publication Digital Edition Sign up for e-alerts Recommend to your library Web feed Subscribe Advertisement View the latest web focus on Systemic Inflammation as a Prognostic Marker in Cancer as well as other collections of papers on key topics.  www.nature.com/bjc/focus   Minireviews Top Improving tumour heterogeneity MRI assessment with histograms N Just Br J Cancer 2014 111: 2205-2213; advance online publication, September 30, 2014; 10.1038/bjc.2014.512 Abstract | Full Text Immune modulation for cancer therapy J Naidoo, D B Page and J D Wolchok Br J Cancer 2014 111: 2214-2219; advance online publication, September 11, 2014; 10.1038/bjc.2014.348 Abstract | Full Text Clinical Studies Top Effects of α-tocopherol and β-carotene supplementation on liver cancer incidence and chronic liver disease mortality in the ATBC study G Y Lai, S J Weinstein, P R Taylor, K A McGlynn, J Virtamo, M H Gail, D Albanes and N D Freedman Br J Cancer 2014 111: 2220-2223; advance online publication, October 14, 2014; 10.1038/bjc.2014.514 Abstract | Full Text The impact of low-grade toxicity in older people with cancer undergoing chemotherapy T Kalsi, G Babic-Illman, P Fields, S Hughes, N Maisey, P Ross, Y Wang and D Harari Br J Cancer 2014 111: 2224-2228; advance online publication, September 30, 2014; 10.1038/bjc.2014.496 Abstract | Full Text Impact of intra-arterial chemotherapy including internal carotid artery for advanced paranasal sinus cancers involving the skull base J Yokoyama, S Ohba, M Fujimaki, T Anzai, M Kojima, K Ikeda, M Suzuki, H Yoshimoto and K Inoue Br J Cancer 2014 111: 2229-2234; advance online publication, September 25, 2014; 10.1038/bjc.2014.501 Abstract | Full Text Pilot study of cytological testing for oesophageal squamous cell dysplasia in a high-risk area in Northern Iran G Roshandel, S Merat, M Sotoudeh, M Khoshnia, H Poustchi, P Lao-Sirieix, S Malhotra, M O'Donovan, A Etemadi, A Nickmanesh, A Pourshams, A Norouzi, I Debiram, S Semnani, C C Abnet, S M Dawsey, R C Fitzgerald and R Malekzadeh Br J Cancer 2014 111: 2235-2241; advance online publication, September 23, 2014; 10.1038/bjc.2014.506 Abstract | Full Text Time dependence of biomarkers: non-proportional effects of immunohistochemical panels predicting relapse risk in early breast cancer J Stephen, G Murray, D A Cameron, J Thomas, I H Kunkler, W Jack, G R Kerr, T Piper, C L Brookes, D W Rea, C J H van de Velde, A Hasenburg, C Markopoulos, L Dirix, C Seynaeve and J M S Bartlett Br J Cancer 2014 111: 2242-2247; advance online publication, October 14, 2014; 10.1038/bjc.2014.530 Abstract | Full Text Tumour responses following a steroid switch from prednisone to dexamethasone in castration-resistant prostate cancer patients progressing on abiraterone D Lorente, A Omlin, R Ferraldeschi, C Pezaro, R Perez, J Mateo, A Altavilla, Z Zafeirou, N Tunariu, C Parker, D Dearnaley, S Gillessen, J de Bono and G Attard Br J Cancer 2014 111: 2248-2253; advance online publication, October 14, 2014; 10.1038/bjc.2014.531 Abstract | Full Text A phase Ib/II translational study of sunitinib with neoadjuvant radiotherapy in soft-tissue sarcoma J Lewin, K K Khamly, R J Young, C Mitchell, R J Hicks, G C Toner, S Y K Ngan, S Chander, G J Powell, A Herschtal, L Te Marvelde, J Desai, P F M Choong, S A Stacker, M G Achen, N Ferris, S Fox, J Slavin and D M Thomas Br J Cancer 2014 111: 2254-2261; advance online publication, October 16, 2014; 10.1038/bjc.2014.537 Abstract | Full Text A Phase I study of cyclin-dependent kinase inhibitor, AT7519, in patients with advanced cancer: NCIC Clinical Trials Group IND 177 E X Chen, S Hotte, H Hirte, L L Siu, J Lyons, M Squires, S Lovell, S Turner, L McIntosh and L Seymour Br J Cancer 2014 111: 2262-2267; advance online publication, November 13, 2014; 10.1038/bjc.2014.565 Abstract | Full Text Phase I study of the halichondrin B analogue eribulin mesylate in combination with cisplatin in advanced solid tumors M Koczywas, P H Frankel, T W Synold, H-J Lenz, J E Mortimer, A B El-Khoueiry, D R Gandara, M C Cristea, V M Chung, D Lim, K L Reckamp, D H Lau, L A Doyle, C Ruel, M I Carroll and E M Newman Br J Cancer 2014 111: 2268-2274; advance online publication, October 28, 2014; 10.1038/bjc.2014.554 Abstract | Full Text Translational Therapeutics Top Interrogation of gossypol therapy in glioblastoma implementing cell line and patient-derived tumour models M A Jarzabek, V Amberger-Murphy, J J Callanan, C Gao, A M Zagozdzon, L Shiels, J Wang, K L Ligon, B E Rich, P Dicker, W M Gallagher, J H M Prehn and A T Byrne Br J Cancer 2014 111: 2275-2286; advance online publication, November 6, 2014; 10.1038/bjc.2014.529 Abstract | Full Text Interleukin-6 mediated upregulation of CYP1B1 and CYP2E1 in colorectal cancer involves DNA methylation, miR27b and STAT3 S A A Patel, U Bhambra, M P Charalambous, R M David, R J Edwards, T Lightfoot, A R Boobis and N J Gooderham Br J Cancer 2014 111: 2287-2296; advance online publication, October 21, 2014; 10.1038/bjc.2014.540 Abstract | Full Text Evidence for a time-dependent association between FOLR1 expression and survival from ovarian carcinoma: implications for clinical testing. An Ovarian Tumour Tissue Analysis consortium study M Köbel, J Madore, S J Ramus, B A Clarke, P D P Pharoah, S Deen, D D Bowtell, K Odunsi, U Menon, C Morrison, S Lele, W Bshara, L Sucheston, M W Beckmann, A Hein, F C Thiel, A Hartmann, D L Wachter, M S Anglesio, E Høgdall, A Jensen, C Høgdall, K R Kalli, B L Fridley, G L Keeney, Z C Fogarty, R A Vierkant, S Liu, S Cho, G Nelson, P Ghatage, A Gentry-Maharaj, S A Gayther, E Benjamin, M Widschwendter, M P Intermaggio, B Rosen, M Q Bernardini, H Mackay, A Oza, P Shaw, M Jimenez-Linan, K E Driver, J Alsop, M Mack, J M Koziak, H Steed, C Ewanowich, A DeFazio, G Chenevix-Trench, S Fereday, B Gao, S E Johnatty, J George, L Galletta, AOCS Study Group, E L Goode, S K Kjær, D G Huntsman, P A Fasching, K B Moysich, J D Brenton and L E Kelemen Br J Cancer 2014 111: 2297-2307; advance online publication, October 30, 2014; 10.1038/bjc.2014.567 Abstract | Full Text Molecular Diagnostics Top Overexpression of nucleostemin contributes to an advanced malignant phenotype and a poor prognosis in oral squamous cell carcinoma R Yoshida, H Nakayama, M Nagata, A Hirosue, T Tanaka, K Kawahara, Y Nakagawa, Y Matsuoka, J Sakata, H Arita, A Hiraki, M Shinohara and T Ito Br J Cancer 2014 111: 2308-2315; advance online publication, October 14, 2014; 10.1038/bjc.2014.539 Abstract | Full Text MiR-204 inhibits human NSCLC metastasis through suppression of NUAK1 L Shi, B Zhang, X Sun, S Lu, Z Liu, Y Liu, H Li, L Wang, X Wang and C Zhao Br J Cancer 2014 111: 2316-2327; advance online publication, November 20, 2014; 10.1038/bjc.2014.580 Abstract | Full Text Inhibition of triple-negative and Herceptin-resistant breast cancer cell proliferation and migration by Annexin A2 antibodies P Chaudhary, S I Thamake, P Shetty and J K Vishwanatha Br J Cancer 2014 111: 2328-2341; advance online publication, October 16, 2014; 10.1038/bjc.2014.542 Abstract | Full Text Spontaneous dormancy of metastatic breast cancer cells in an all human liver microphysiologic system S E Wheeler, A M Clark, D P Taylor, C L Young, V C Pillai, D B Stolz, R Venkataramanan, D Lauffenburger, L Griffith and A Wells Br J Cancer 2014 111: 2342-2350; advance online publication, October 14, 2014; 10.1038/bjc.2014.533 Abstract | Full Text Genetics and Genomics Top Mutational profiling of familial male breast cancers reveals similarities with luminal A female breast cancer with rare TP53 mutations S Deb, S Q Wong, J Li, H Do, J Weiss, D Byrne, A Chakrabarti, T Bosma, kConFab Investigators8, A Fellowes, A Dobrovic and S B Fox Br J Cancer 2014 111: 2351-2360; 10.1038/bjc.2014.511 Abstract | Full Text MicroRNA expression profiling in male and female familial breast cancer R Pinto, S De Summa, K Danza, O Popescu, A Paradiso, L Micale, G Merla, O Palumbo, M Carella and S Tommasi Br J Cancer 2014 111: 2361-2368; advance online publication, November 13, 2014; 10.1038/bjc.2014.535 Abstract | Full Text Letters to the Editor Top Comment on ‘TAp63 suppress metastasis via miR-133b in colon cancer cells’ I Cristobal, J Madoz-Gurpide, E Martin-Aparicio, C Carames, O Aguilera, F Rojo and J Garcia-Foncillas Br J Cancer 2014 111: 2369; advance online publication, July 24, 2014; 10.1038/bjc.2014.390 Full Text Response to comment on ‘TAp63 suppress metastasis via miR-133b in colon cancer cells’ C W Lin, X R Li, Y Zhang, G Hu, Y H Guo, J Y Zhou, J Du, L Lv, K Gao, Y Zhang and H Deng Br J Cancer 2014 111: 2369-2370; 10.1038/bjc.2014.389 Full Text Comment on ‘Pre-operative nomogram for the identification of lymph node metastasis in early cervical cancer’ A Buda, L Guerra and C Crivellaro Br J Cancer 2014 111: 2370-2371; advance online publication, August 14, 2014; 10.1038/bjc.2014.284 Full Text Response to comment on ‘Preoperative nomogram for the identification of lymph node metastasis in early cervical cancer’ J-H Nam, D-Y Kim and S-H Shim Br J Cancer 2014 111: 2371; advance online publication, August 14, 2014; 10.1038/bjc.2014.330 Full Text Comment on ‘Tumour-infiltrating inflammation and prognosis in colorectal cancer: systematic review and meta-analysis’ J H Park, C S D Roxburgh and D C McMillan Br J Cancer 2014 111: 2372; advance online publication, October 28, 2014; 10.1038/bjc.2014.296 Full Text Response to comment on ‘Tumour-infiltrating inflammation and prognosis in colorectal cancer: systematic review and meta-analysis’ Z Mei, Y Liu, C Liu and L Cui Br J Cancer 2014 111: 2372-2373; advance online publication, October 28, 2014; 10.1038/bjc.2014.285 Full Text Comment on ‘Characteristics and screening history of women diagnosed with cervical cancer aged 20–29’ A Herbert, G Holdsworth and A A Kubba Br J Cancer 2014 111: 2373-2374; advance online publication, August 28, 2014; 10.1038/bjc.2014.464 Full Text Response to comment on ‘Characteristics and screening history of women diagnosed with cervical cancer aged 20–29’ A Castanon, R Landy, A W Lim and P Sasieni Br J Cancer 2014 111: 2374; advance online publication, August 28, 2014; 10.1038/bjc.2014.465 Full Text Comment on ‘External multicentre validation of a nomogram predicting the risk of relapse in patients with borderline ovarian tumours’ A Obermair Br J Cancer 2014 111: 2375; advance online publication, January 21, 2014; 10.1038/bjc.2014.8 Full Text Response to ‘Comment on external multicentre validation of a nomogram predicting the risk of relapse in patients with borderline ovarian tumours’ S Bendifallah and E Darai Br J Cancer 2014 111: 2375-2376; advance online publication, April 22, 2014; 10.1038/bjc.2014.216 Full Text Comment on ‘Existing prognostic models, but not neutrophil-to-lymphocyte ratio, are prognostic in malignant mesothelioma’ S C-H Kao, N van Zandwijk and S Clarke Br J Cancer 2014 111: 2376; advance online publication, April 8, 2014; 10.1038/bjc.2014.185 Full Text Response to comment on ‘Existing prognostic models, but not neutrophil-to-lymphocyte ratio, are prognostic in malignant mesothelioma’ T M Meniawy, J Creaney, R A Lake and A K Nowak Br J Cancer 2014 111: 2377; advance online publication, April 8, 2014; 10.1038/bjc.2014.187 Full Text Comment on ‘Interventions to improve exercise behaviour in sedentary people living with and beyond cancer: a systematic review’ J M Broderick, J Hussey and D M O’Donnell Br J Cancer 2014 111: 2377-2378; advance online publication, May 8, 2014; 10.1038/bjc.2014.248 Full Text Response to comment on ‘Interventions to improve exercise behaviour in sedentary people living with and beyond cancer: a systematic review’ L Bourke, D J Rosario, L Steed and S J C Taylor Br J Cancer 2014 111: 2378-2379; advance online publication, May 27, 2014; 10.1038/bjc.2014.249 Full Text Comment on ‘KRAS-mutated plasma DNA as predictor of outcome from irinotecan monotherapy in metastatic colorectal cancer’ D Tougeron, P Laurent-Puig and A Zaanan Br J Cancer 2014 111: 2379-2380; advance online publication, March 11, 2014; 10.1038/bjc.2014.114 Full Text Response to comment on ‘KRAS-mutated plasma DNA as predictor of outcome from irinotecan monotherapy in metastatic colorectal cancer’ K-L G Spindler, N Pallisgaard, R F Andersen and A Jakobsen Br J Cancer 2014 111: 2380; advance online publication, March 11, 2014; 10.1038/bjc.2014.115 Full Text Corrigenda Top Abnormal expression and function of the E-cadherin–catenin complex in gastric carcinoma cell lines A U Jawhari, M Noda, M J G Farthing and M Pignatelli Br J Cancer 2014 111: 2381; 10.1038/bjc.2014.615 Full Text Estimating the asbestos-related lung cancer burden from mesothelioma mortality V McCormack, J Peto, G Byrnes, K Straif and P Boffetta Br J Cancer 2014 111: 2381; 10.1038/bjc.2014.616 Full Text Farnesoid X receptor, overexpressed in pancreatic cancer with lymph node metastasis promotes cell migration and invasion J Y Lee, K T Lee, J K Lee, K H Lee, K-T Jang, J S Heo, S H Choi, Y Il Kim and J C Rhee Br J Cancer 2014 111: 2381; advance online publication, July 31, 2014; 10.1038/bjc.2014.449 Full Text Differences in cancer awareness and beliefs between Australia, Canada, Denmark, Norway, Sweden and the UK (the International Cancer Benchmarking Partnership): do they contribute to differences in cancer survival? L J L Forbes, A E Simon, F Warburton, D Boniface, K E Brain, A Dessaix, C Donnelly, K Haynes, L Hvidberg, M Lagerlund, G Lockwood, C Tishelman, P Vedsted, M N Vigmostad, A J Ramirez and J Wardle the International Cancer Benchmarking Partnership Module 2 Working Group Br J Cancer 2014 111: 2382; 10.1038/bjc.2014.562 Full Text Randomised phase II study of S-1/cisplatin plus TSU-68 vs S-1/cisplatin in patients with advanced gastric cancer W Koizumi, K Yamaguchi, H Hosaka, Y Takinishi, N Nakayama, T Hara, K Muro, H Baba, Y Sasaki, T Nishina, N Fuse, T Esaki, M Takagi, M Gotoh and T Sasaki Br J Cancer 2014 111: 2382; 10.1038/bjc.2014.550 Full Text Combined analysis of HLA class I, HLA-E and HLA-G predicts prognosis in colon cancer patients E C M Zeestraten, M S Reimers, S Saadatmand, I J Goossens-Beumer, J-W T Dekker, G J Liefers, P J van den Elsen, C J H van de Velde and P J K Kuppen Br J Cancer 2014 111: 2383; 10.1038/bjc.2014.549 Full Text MiR-224 promotes the chemoresistance of human lung adenocarcinoma cells to cisplatin via regulating G1/S transition and apoptosis by targeting p21WAF1/CIP1 H Wang, L-J Zhu, Y-C Yang, Z-X Wang and R Wang Br J Cancer 2014 111: 2383; 10.1038/bjc.2014.551 Full Text Erratum Top Relationships between pazopanib exposure and clinical safety and efficacy in patients with advanced renal cell carcinoma A B Suttle, H A Ball, M Molimard, T E Hutson, C Carpenter, D Rajagopalan, Y Lin, S Swann, R Amado and L Pandite Br J Cancer 2014 111: 2383; 10.1038/bjc.2014.627 Full Text Index Top Author Index for Volume111 Br J Cancer 2014 111: 2384-2392; 10.1038/bjc.2014.617 Full Text Keyword Index for Volume 111 Br J Cancer 2014 111: 2393-2396; 10.1038/bjc.2014.618 Full Text Please note that you need to be a subscriber or site-licence holder to enjoy full-text access to British Journal of Cancer. In order to do so, please purchase a subscription. You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/nams/svc/myaccount (You will need to log in to be recognised as a nature.com registrant). For further technical assistance, please contact our registration department. For print subscription enquiries, please contact our subscription department. For other enquiries, please contact our customer feedback department. Nature Publishing Group | 75 Varick Street, 9th Floor | New York | NY 10013-1917 | USA Nature Publishing Group's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at Brunel Road, Houndmills, Basingstoke, Hampshire RG21 6XS. © 2014 Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.